Dublin, Jan. 22, 2016 -- Research and Markets (http://www.researchandmarkets.com/research/grf74m/molecular) has announced the addition of Jain PharmaBiotech's new report "Molecular Diagnostics - Technologies, Markets and Companies" to their offering.
This report describes and evaluates the molecular diagnostics technologies that will play an important role in practice of medicine, public health, pharmaceutical industry, forensics and biological warfare in the 21st century. This includes several polymerase chain reaction (PCR)-based technologies, fluorescent in situ hybridization (FISH), peptide nucleic acids (PNA), electrochemical detection of DNA, sequencing, mitochondrial DNA, biochips, nanotechnology and proteomic technologies.
Initial applications of molecular diagnostics were mostly for infections but are now increasing in the areas of genetic disorders, preimplantation screening and cancer. Genetic screening tests, despite some restrictions is a promising area for future expansion of in vitro diagnostic market. Molecular diagnostics is being combined with therapeutics and forms an important component of integrated healthcare. Molecular diagnostic technologies are also involved in development of personalized medicine based on pharmacogenetics and pharmacogenomics. Currently, there has been a considerable interest in developing rapid diagnostic methods for for point-of-care and biowarfare agents such as anthrax.
The number of companies involved in molecular diagnostics has increased remarkably during the past few years. More than 1,000 companies have been identified to be involved in developing molecular diagnostics and 340 of these are profiled in the report along with tabulation of 808 collaborations. Despite the strict regulation, most of the development in molecular diagnostics has taken place in the United States, which has the largest number of companies.
The markets for molecular diagnostics technologies are difficult to estimate. Molecular diagnostics markets overlap with markets for non-molecular diagnostic technologies in the in vitro diagnostic market and are less well defined than those for pharmaceuticals. Molecular diagnostic markets are analyzed for 2015 according to technologies, applications and geographical regions. Forecasts are made up to 2025. A major portion of the molecular diagnostic market can be attributed to advances in genomics and proteomics. Biochip and nanobiotechnology are expected to make a significant contribution to the growth of molecular diagnostics.
Key Topics Covered:
Part I: Technologies & Applications
1. Introduction
2. Molecular Diagnostic Technologies
3 DNA dendrimer signal amplification
3. Biochips, Biosensors, and Nanobiotechnology
4. Proteomic Technologies for Molecular Diagnostics
5. Molecular Diagnosis of Genetic Disorders
6. Molecular diagnosis of cardiovascular disorders
7. Molecular Diagnosis of Infections
8. Molecular Diagnosis of Cancer
9. Molecular Diagnostics in Biopharmaceutical Industry & Healthcare
10. Molecular Diagnostics in Forensic Medicine and Biological Warfare
11. References
Part II: Regulations, Markets & Companies
12. Ethics, Patents and Regulatory issues
13. Markets for Molecular Diagnostics
14. Companies involved in molecular diagnostics
For more information visit http://www.researchandmarkets.com/research/grf74m/molecular
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: In Vitro Diagnostics, Molecular Diagnostics


OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Instagram Outage Disrupts Thousands of U.S. Users
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 



